Thoracic Surgery Division, Department of Cardiac, Thoracic, Vascular Sciences, and Public Health, Padova University Hospital, Padova, Italy.
Thoracic Surgery Division, Department of Cardiac, Thoracic, Vascular Sciences, and Public Health, Padova University Hospital, Padova, Italy.
Ann Thorac Surg. 2021 Dec;112(6):1805-1813. doi: 10.1016/j.athoracsur.2020.12.029. Epub 2021 Jan 9.
The treatment of non-small cell lung cancer is based, when suitable, on surgical resection. Pneumonectomy has been considered the standard surgical procedure for locally advanced lung cancers but it is associated with high mortality and morbidity rates. Reconstruction of the pulmonary artery, associated with parenchyma-sparing techniques, is meant to be an alternative to pneumonectomy.
This retrospective single-center study is based on a detailed and comprehensive analysis of the clinical and oncologic data of patients treated between 2004 and 2016 through pneumonectomy or lobectomy with reconstruction of the pulmonary artery. A propensity score weighting approach, based on the preoperative characteristics of two groups of 124 patients each was performed. The subsequent statistical analysis evaluated long-term and short-term clinical outcomes together with risk factors analysis.
The comparison between pneumonectomy and pulmonary artery reconstructions showed a higher 30-day (P = .02) and 90-day (P = .03) mortality rate in the pneumonectomy group, together with a higher incidence of major complications (P = .004). Long-term results have shown comparable outcomes, both in terms of 5-year disease-free survival (52.2% for pneumonectomy vs 46% for pulmonary artery reconstructions, P = .57) and overall 5-year survival (41.9% vs 35.6%, respectively; P = .57). Risk factors analysis showed that cancer-specific survival was related to lymph node status (P < .01) and absence of adjuvant therapy (P = .04). Lymph node status also influenced the risk of recurrence (P < .01).
Lobectomy with reconstruction of the pulmonary artery is a valuable and oncologically safe alternative to pneumonectomy, with lower short-term mortality and morbidity, without affecting long-term oncologic results.
非小细胞肺癌的治疗方法是基于手术切除的。当适合时,肺切除术被认为是局部晚期肺癌的标准手术方法,但它与高死亡率和发病率有关。肺动脉重建与保留肺实质技术相结合,被认为是肺切除术的替代方法。
本回顾性单中心研究基于对 2004 年至 2016 年间通过肺切除术或肺叶切除术联合肺动脉重建治疗的 124 例患者的临床和肿瘤学数据进行的详细和全面分析。采用倾向评分加权法,对两组各 124 例患者的术前特征进行分析。随后的统计分析评估了长期和短期的临床结果,并分析了危险因素。
肺切除术与肺动脉重建的比较显示,肺切除术组 30 天(P =.02)和 90 天(P =.03)死亡率较高,且主要并发症发生率较高(P =.004)。长期结果显示,两组在 5 年无病生存率(肺切除术组为 52.2%,肺动脉重建组为 46%,P =.57)和总体 5 年生存率(分别为 41.9%和 35.6%,P =.57)方面具有可比性。危险因素分析显示,癌症特异性生存率与淋巴结状态有关(P <.01),与辅助治疗无关(P =.04)。淋巴结状态也影响复发风险(P <.01)。
肺叶切除术联合肺动脉重建是一种有价值的、肿瘤学上安全的肺切除术替代方法,短期死亡率和发病率较低,不影响长期肿瘤学结果。